The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain. IBRANCE® (palbociclib) Prescribing Information for Great Britain click here. IBRANCE® (palbociclib) Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
Confidence In A Treatment that’s Setting The Standard1-4
The efficacy and safety of IBRANCE® has been evaluated in two large Randomised Control Trials (RCTs) in women with HR+/HER2- metastatic Breast Cancer (mBC) as part of Pfizer’s robust PALOMA Clinical Trial Programme in breast cancer.1-4
IBRANCE® + Aromatase Inhibitor (AI) PALOMA-2 clinical trial results including efficacy and safety outcomes.
IBRANCE® safety information and frequent adverse events
Real-world evidence for IBRANCE® (palbociclib) in advanced Breast Cancer
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
IBRANCE® + Aromatase Inhibitor (AI) Clinical Trial Results
IBRANCE® safety information and outcomes
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020